@article{22346,
      note = {Price : 51.52; Inv.# CH52902; Date 11/08/98; Supplier :  CroftHouse, UK; Recd 25/08/98; Contents : 1. Patent law  primer; 2. Recombinant products and the standard for  obviousness : a typology; 3. In re Deuel : the Federal  circuit and "translation" DNAs; 4. Generalization of a  concept : other biotechnology products are "translation"  inventions; 5. Consequences and remedies;.},
      author = {Ducor, Philippe Georges, and Ducor, Phillipe G.},
      url = {http://tind.wipo.int/record/22346},
      title = {Patenting the recombinant products of biotechnology /},
      abstract = {This work examines the requirements for patentability in  the context of biotechnology, with a special focus on non  obviousness. Reviewing the relevant case law, it analyses  thoroughly non obviousness as applied to biotechnology  molecular products. It first offers a typology of  recombinant inventions, useful in determining ultimate non  obviousness and patentability. Three categories of  recombinant products are distinguished. "Translation"  inventions, obtained by entering a known molecular  information into a known process. "Molecular modification"  products, obtained by modifying prior art molecules.  "Combination" inventions, obtained by combining several  known functional molecular units. Recognizing that many  "translation" inventions are at risk of being considered  obvious upon maturation of the underlying technology, the  author examines possible alternatives for protection.},
      recid = {22346},
      pages = {xvii, 179 pages :},
}